v3.26.1
Segment Reporting (Details)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Jun. 30, 2026
USD ($)
segment
Jun. 30, 2025
USD ($)
Segment Reporting [Abstract]        
Number of reportable segments | segment     2  
Segment Reporting [Line Items]        
Impact of foreign currency fluctuations $ 2 $ (29) $ 3 $ (133)
Net sales 5,442 5,061 10,646 9,724
Segment operating income 1,795 1,685 3,453 3,290
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments (2,670) (2,605) (5,183) (4,894)
Goodwill and other intangible asset impairment charges, acquisition/divestiture-related net charges (credits), restructuring and restructuring-related net charges (credits), certain litigation-related net charges (credits), EU MDR implementation costs, and the IEEPA tariff refund (132) (355) (258) (564)
Amortization expense (233) (225) (466) (444)
Operating income (loss) 1,178 819 2,279 1,740
Other income (expense), net (118) 122 (57) 6
Income (loss) before income taxes 1,060 941 2,222 1,746
MedSurg        
Segment Reporting [Line Items]        
Net sales 1,818 1,716 3,519 3,293
Cardiovascular        
Segment Reporting [Line Items]        
Net sales 3,624 3,345 7,126 6,430
Operating Segments        
Segment Reporting [Line Items]        
Net sales of reportable segments 5,440 5,090 10,643 9,856
Income (loss) before income taxes   941    
Operating Segments | MedSurg        
Segment Reporting [Line Items]        
Net sales of reportable segments 1,818 1,725 3,518 3,335
Cost of products sold $ 526 $ 470 $ 1,004 $ 906
Cost of products sold, percentage of net sale 28.90% 27.30% 28.50% 27.20%
Selling, general and administrative expenses $ 567 $ 521 $ 1,124 $ 1,033
Selling, general and administrative expenses, percentage of net sale 31.20% 30.20% 31.90% 31.00%
Research and development expenses $ 124 $ 120 $ 251 $ 241
Research and development expenses, percentage of net sale 6.80% 7.00% 7.10% 7.20%
Other segment items $ 4 $ 8 $ 9 $ 13
Other segment items, percentage of net sale 0.20% 0.40% 0.30% 0.40%
Segment operating income $ 598 $ 606 $ 1,130 $ 1,142
Segment operating income, percentage of net sale 32.90% 35.10% 32.10% 34.20%
Operating Segments | Cardiovascular        
Segment Reporting [Line Items]        
Net sales of reportable segments $ 3,622 $ 3,365 $ 7,124 $ 6,522
Cost of products sold $ 1,065 $ 1,048 $ 2,133 $ 1,975
Cost of products sold, percentage of net sale 29.40% 31.20% 29.90% 30.30%
Selling, general and administrative expenses $ 992 $ 915 $ 1,952 $ 1,788
Selling, general and administrative expenses, percentage of net sale 27.40% 27.20% 27.40% 27.40%
Research and development expenses $ 359 $ 316 $ 702 $ 600
Research and development expenses, percentage of net sale 9.90% 9.40% 9.90% 9.20%
Other segment items $ 8 $ 6 $ 15 $ 12
Other segment items, percentage of net sale 0.20% 0.20% 0.20% 0.20%
Segment operating income $ 1,197 $ 1,079 $ 2,323 $ 2,148
Segment operating income, percentage of net sale 33.10% 32.10% 32.60% 32.90%
Segment Reporting, Reconciling Item, Corporate Nonsegment        
Segment Reporting [Line Items]        
Corporate expenses, including hedging activities and impact of foreign currency fluctuations on operating income of reportable segments $ (252) $ (286) $ (451) $ (541)